Literature DB >> 18536680

The FDA and safety--beyond the heparin crisis.

Cato T Laurencin1, Lakshmi Nair.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18536680     DOI： 10.1038/nbt0608-621

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro.

Authors:  Albert Adam; Nicolas Montpas; David Keire; Anik Désormeaux; Nancy J Brown; François Marceau; Benjamin Westenberger
Journal:  Biomaterials       Date:  2010-04-27       Impact factor: 12.479

2.  In vitro and in vivo characterization of a reversible synthetic heparin analog.

Authors:  Matthew F Whelihan; Brian Cooley; Yongmei Xu; Rafal Pawlinski; Jian Liu; Nigel S Key
Journal:  Thromb Res       Date:  2015-12-10       Impact factor: 3.944

Review 3.  Lessons learned from the contamination of heparin.

Authors:  Haiying Liu; Zhenqing Zhang; Robert J Linhardt
Journal:  Nat Prod Rep       Date:  2009-01-19       Impact factor: 13.423

4.  Heparins: A Shift of Paradigm.

Authors:  H Coenraad Hemker; Raed Al Dieri; Suzette Béguin
Journal:  Front Med (Lausanne)       Date:  2019-11-15

5.  Complete biosynthesis of a sulfated chondroitin in Escherichia coli.

Authors:  Abinaya Badri; Asher Williams; Adeola Awofiranye; Payel Datta; Ke Xia; Wenqin He; Keith Fraser; Jonathan S Dordick; Robert J Linhardt; Mattheos A G Koffas
Journal:  Nat Commun       Date:  2021-03-02       Impact factor: 14.919
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.